American Invest Hub
  • Politics
  • Investing
  • Business
  • Latest News

American Invest Hub

  • Politics
  • Investing
  • Business
  • Latest News
Business

Bristol Myers CEO explains why he’s spending billions on BioNTech deal

by admin June 3, 2025
June 3, 2025
Bristol Myers CEO explains why he’s spending billions on BioNTech deal

Bristol-Myers Squibb Co (NYSE: BMY) is inching up on Monday after announcing an $11 billion deal with BioNTech SE (Nasdaq: BNTX) aimed at transforming cancer treatment.

The pharmaceutical behemoth announced the said partnership at ASCO, the world’s largest cancer conference in Chicago.

Despite today’s price action, BMY shares are down some 25% versus their year-to-date high.

Speaking this morning with CNBC, Christopher Boerner – chief executive of Bristol Myers offered three big reasons for the blockbuster collaboration with the Germany based BioNTech.

1. Targeting hard-to-treat tumors with breakthrough science

According to Christopher Boerner, the BioNTech deal stems from the company’s commitment to one mission: tackling some of the most challenging solid tumours where current treatments fall short.

The collaboration will focus on next-gen immunotherapies, particularly bispecific antibodies that aim to improve outcomes in cancers like lung and triple-negative breast cancer.

“This could be the next new frontier in the treatment of cancer,” Boerner told CNBC, adding that immune-oncology (IO) drugs may have changed the landscape for many cancers, but lasting remission is still seen in about 30% of the patients only.

That leaves a large pool of patients with unmet medical needs – patients that Bristol Myers and BNTX are hoping to reach.

At the core of the announced team-up is a promising drug candidate that combines VEGF and PD-L1 inhibition in a single bispecific molecule, potentially leading to more durable responses.

“We really like the science,” Boerner noted, calling the bispecific approach a potential game-changer.

2. Strategic positioning for first mover advantage in key markets

Beyond the science, the deal is also about gaining a competitive edge.

Boerner highlighted the importance of timing in a crowded oncology market during the interview, saying what he’s learned from his experience in immuno-oncology is “if you want to capture value in highly competitive spaces, you need to be first or second.”

According to the chief executive, BioNTech’s assets are well-positioned to become early entrants across several high-value tumor types.

That timing could give BMY the kind of foothold needed to secure commercial success. The company’s existing expertise in marketing and distributing oncology products further strengthens its chances to maximize the value of the deal.

3. Doubling Down on Long-Term Growth Potential

The BioNTech partnership is not just about short-term results, Boerner sees it as a long-term growth engine for the pharma stock as the decade unfolds.

With some of its legacy IO products facing patent cliffs, BMS needs new therapies to fuel future revenues. This collaboration offers that potential, pairing BioNTech’s cutting-edge science with BMY’s commercialization capabilities.

“This deal gives us another leg for growth as we exit this decade,” Boerner said. With BioNTech’s pipeline complementing Bristol Myers’ strategy, the partnership could evolve into a foundational element of the company’s oncology business.

In a high-stakes, high-reward field, BMY is betting big – but with a clear vision of where the science and market are heading. If successful, the partnership could reshape cancer treatment and deliver billions in future returns.

The post Bristol Myers CEO explains why he’s spending billions on BioNTech deal appeared first on Invezz

0
FacebookTwitterGoogle +Pinterest
previous post
Here’s why private equity stocks like Blackstone, KKR, Apollo have crashed
next post
Brazil’s Cemig shares hold ground as bullish momentum persists despite minor setback

Related Posts

Tesco share price forecast in September: will it...

September 1, 2025

FTSE 100 forecast ahead of Barclays, Unilever, BAT,...

February 7, 2025

Dow and S&P slip on rising trade tensions;...

March 13, 2025

TSLY and NVDY ETFs brace for key events:...

October 8, 2024

Meta to pay $25 million to Trump to...

January 30, 2025

The housing crunch is still squeezing buyers —...

July 31, 2024

Dow Jones, S&P 500 rise on strong US...

November 24, 2024

Two US tech stocks on the verge of...

March 29, 2025

Gold ETFs gain momentum as investors seek safe-haven...

August 23, 2025

Dave & Buster’s plan to allow betting on...

May 10, 2024

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Latest News

    • Europe bulletin: Manchester synagogue attack aftermath, stocks close higher

      October 5, 2025
    • Evening digest: Trump sets deadline for Hamas, Canada’s slowdown, BTC rebounds

      October 5, 2025
    • Iran executes six people for alleged links to Israel, state media reports

      October 5, 2025
    • US digest: Trump’s Hamas ultimatum, government shutdown stalemate continues

      October 5, 2025
    • Japanese stocks may extend record run as Takaichi win revives ‘Abenomics’

      October 5, 2025

    Categories

    • Business (4,191)
    • Investing (2,958)
    • Latest News (2,080)
    • Politics (1,536)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: americaninvesthub.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2025 americaninvesthub.com | All Rights Reserved